New Weight-Loss shot passes early safety check in 102 volunteers
NCT ID NCT06762600
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new injection called HRS-4729 in 102 healthy adults who were overweight or obese. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects, weight changes, and drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
102 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Voluntarily provides written informed consent prior to the initiation of any study-related activities and demonstrates understanding of the procedures and methods involved in the study, agreeing to adhere strictly to the clinical trial protocol to complete the study. 2. Male or female subjects; aged 18 to 55 years. 3. Self-reports no more than a 5 kg change in body weight during the 3 months prior to screening (including the screening visit). Exclusion Criteria: 1. A history of current significant disease in the neurological, psychiatric, cardiovascular, gastrointestinal, respiratory, genitourinary, endocrine, hematologic, or immune systems, as determined by the investigator, which would render the subject unsuitable for participation in this trial. 2. A history of significant gastrointestinal disease or related symptoms, conditions affecting gastric emptying, or prior gastrointestinal surgery. 3. Subjects who have had a major surgery or severe trauma within 6 months prior to screening, or who are planned for surgical procedures during the trial period. 4. Participation in any drug or medical device clinical trial within 3 months prior to screening. 5. Any abnormal physical examination, vital signs, laboratory tests, chest X-ray and abdominal ultrasound findings deemed clinically significant by the investigator, rendering the subject unsuitable for participation. 6. Clinically significant abnormalities on 12-lead ECG as determined by the investigator. 7. Known or suspected history of drug abuse or substance dependence, or positive urine drug screen during the screening period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an experimental injection help people with obesity shed pounds?
- A cup of beans a day: could it calm inflammation and boost insulin response?
- Can a new pill help fight obesity? a trial puts HRS-7535 to the test
- Could shedding pounds be the key to silencing chronic back pain?
- Could a new injection help tackle obesity? a safety trial begins
- Can a new injection help tackle obesity and diabetes? a safety trial begins